Companies / RCE

RECCE PHARMACEUTICALS LTD

ASX:RCEPharmaceuticals, Biotechnology & Life Sciences
299.5M shares on issueASX (delayed) · as of 28 July 2026$0.38price · delayed$107.8Mmarket cap · indicative
C
Dilution grade

Share count grew 35% in 24 months; runway 4–8 quarters; 1 cash raise in 24 months

Cash runway5.8 quarters of funding
Share-count growth (24m)35.0%
Raise cadence (24m)1 cash raise
Options & rights overhang9.7% of shares
In-the-money supply0.0% of shares
Pending proposed issuesopen proposed issue (Appendix 3B)

RECCE PHARMACEUTICALS LTD's ordinary share count grew 35.0% between July 2024 and July 2026 to 299M shares. The company raised capital once in that period, a Placement / Share Purchase Plan (SPP) that raised A$8.0M in June 2026, for total proceeds of A$8.0M. Options and rights could convert into 29M new shares, equal to 9.7% of the current share count, with 0% in the money and the nearest expiry in February 2027. At the June 2026 quarter the company reported A$13.8M in cash, covering 5.8 quarters at its recent spending rate. One proposed securities issue (Appendix 3B) is pending with a nearest proposed date of July 2026.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
9.7%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
5.8 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 299.5M per ASX (delayed) (28 July 2026).
246.1M265.7M285.3MDec 24Sept 25July 26Cash raise · 23 June 2026

Cash runway

5.8 qtrs
More than four quarters of funding at the recent spend rate.
$13.8M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
3 July 20262A · quoted issueRCE : ORDINARY FULLY PAID299.5MAppendix 2A
2 July 20263H · cancellationRCE : ORDINARY FULLY PAID299.3MAppendix 3H
1 July 20262A · quoted issueRCE : ORDINARY FULLY PAID299.0MAppendix 2A
1 July 20262A · quoted issueRCE : ORDINARY FULLY PAID289.4MAppendix 2A
1 July 20262A · quoted issueRCE : ORDINARY FULLY PAID289.2MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$8.0M
Placement / Share Purchase Plan (SPP)
23 June 2026 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

1 proposed issue pending — Appendix 3B lodged, securities not yet issued. New shares from these issues are not in the counts above until quoted.
Paid plan
Pending issue detail
Size, price, fees, broker and placement-capacity usage for each pending issue.
Join the waitlist

Options & convertible securities

9.7%
Total overhang · of current shares
0.0%
In the money · at current price
29.1M
Potential new shares
Feb 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
22 Feb 2026Dr Justin WardOther352k1.0M—3Y notice
22 Feb 2026James GrahamOther6.8M——3Y notice
22 Feb 2026Dr Alan DuntonOther146k2.3M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

21 July 2026Investor Webinar - Q4 FY26 Investor Presentation Deck
21 July 2026Investor Webinar - 2.30PM (AEST) 21 July 2026
21 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
19 July 2026Update - Proposed issue of securities - RCE
19 July 2026Extension to Share Purchase Plan Closing Date
13 July 2026$PVietnamese Patent Granted for RECCE Anti-Infectives
5 July 2026Share Purchase Plan - Letter and Offer Booklet
3 July 2026Cleansing Notice
3 July 2026Application for quotation of securities - RCE
2 July 2026Notification of cessation of securities - RCE
1 July 2026Cleansing Notice
1 July 2026Application for quotation of securities - RCE
1 July 2026Application for quotation of securities - RCE
1 July 2026Application for quotation of securities - RCE
30 June 2026$PAUD $3.7M Income Tax Refund Received
26 June 2026Proposed issue of securities - RCE
26 June 2026RCE Investor Presentation
26 June 2026Proposed issue of securities - RCE
26 June 2026$PPlacement & SPP to raise $8 million
24 June 2026$PTrading Halt

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.